SK Bio

SK Biopharmaceuticals is a global pharmaceutical company based in South Korea that specializes in the research, development, and commercialization of therapies for central nervous system (CNS) disorders and oncology. The company is distinguished as the first Korean entity to independently develop and obtain FDA approval for an innovative drug, XCOPRI (cenobamate), used for treating partial-onset seizures in adults. SK Biopharmaceuticals leverages an advanced R&D platform that integrates artificial intelligence to accelerate drug discovery and optimize clinical success. Beyond its established CNS portfolio, the company is aggressively expanding into next-generation modalities, including radiopharmaceutical therapy (RPT) and targeted protein degradation (TPD). Through its U.S. subsidiary, SK Life Science, the company maintains a robust commercial infrastructure to support its global growth strategy.